Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 Biomarker disease BEFREE There is solid evidence supporting the use of BRAF status as a prognostic biomarker and DYPD, UGT1A1, RAS, and microsatellite instability as predictive biomarkers in mCRC. 31347092 2019
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 GeneticVariation disease BEFREE The present study was designed to investigate the relationship between UGT1A1 polymorphisms and the incidence of adverse events or the therapeutic effect in mCRC patients who received irinotecan. 30377777 2019
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 Biomarker disease BEFREE To evaluate the efficacy and toxicities of regorafenib plus irinotecan, dose-escalated on the basis of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping, in previously heavily treated metastatic colorectal cancer (mCRC) and the prognostic values of EGFR expression, KRAS mutations, and tumor sidedness. 30594039 2019
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 GeneticVariation disease BEFREE Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy. 28278081 2017
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 Biomarker disease BEFREE Our findings indicate that regorafenib plus FOLFIRI with irinotecan dose escalation based on UGT1A1 genotyping in previously treated patients with mCRC and with UGT1A1*1/*1 and UGT1A1*1/*28 genotypes is clinically effective and yields improved oncological outcomes. 27938508 2017
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 GeneticVariation disease BEFREE To verify the genotyping effectiveness of this newly developed DNA microarray we examined UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphisms in DNA extracted from patients with metastatic colorectal cancer. 28474802 2017
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 Biomarker disease BEFREE This study evaluates the cost-effectiveness of UGT1A1 genotyping in patients with metastatic colorectal cancer undergoing irinotecan-based chemotherapy compared to no testing from the perspective of the German statutory health insurance. 26098842 2016
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 GeneticVariation disease BEFREE This trial is a prospective, multicenter, randomized clinical trial comparing UGT1A1 promoter polymorphism for irinotecan dose escalation in mCRC patients administered with bevacizumab plus FOLFIRI as the first-line setting. 26811156 2016
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 GeneticVariation disease BEFREE The purpose of this study was to determine the associations between UGT1A1(*)28 and (*)6 polymorphisms and irinotecan toxicity in Thai patients with metastatic colorectal cancer. 26830078 2016
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 Biomarker disease BEFREE CoBil and UGT1A1*28 are both independent biomarkers for predicting the treatment response of mCRC patients to irinotecan-based chemotherapy. 27122675 2016
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 Biomarker disease BEFREE A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients. 27160286 2016
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 GeneticVariation disease BEFREE This phase II study aimed to evaluate the combination of high-dose FOLFIRI plus bevacizumab in patients with previously untreated metastatic colorectal cancer (MCRC) based on their UGT1A1 genotype. 26494856 2015
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 GeneticVariation disease BEFREE A phase I study of UGT1A1 *28/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRI. 25427841 2015
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 Biomarker disease BEFREE Patients with mCRC who had received prior chemotherapy including oxaliplatin and BV and had a UGT1A1 genotype of wild-type or heterozygous for UGT1A1*6 or *28 were eligible for this study. 25834402 2015
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 Biomarker disease BEFREE By characterizing the UGT1 sequence from a cohort of 167 Canadian metastatic colorectal cancer (mCRC) patients and a validation cohort of 250 Italian mCRC patients, we found rs11563250G, located in the intergenic region downstream of UGT1, to be significantly associated with reduced risk of severe neutropenia (odds ratio (OR)=0.21; P=0.043 and OR=0.27; P=0.036, respectively, and OR=0.31 when combined; P=0.001), which remained significant upon correction for multiple testing in the combined cohort (P=0.041). 25778466 2015
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 Biomarker disease BEFREE Patients with mCRC undergoing UGT1A1 genotyping may receive escalated doses of irinotecan to obtain a better clinical response/outcome with comparable toxicities. 24462762 2014
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 GeneticVariation disease BEFREE To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping. 24642571 2014
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 GeneticVariation disease BEFREE UGT1A1*6 (211G>A), UGT1A1*28 (TA6>TA7), UGT1A1*60 (-3279T>G), UGT1A7 (387T>G), UGT1A7 (622T>C), and UGT1A9*1b (-118T9>T10, also named *22) were genotyped in 123 patients with metastatic colorectal cancer who had received irinotecan-based chemotherapy. 25175642 2014
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 GeneticVariation disease BEFREE We report here a case of a metastatic colorectal cancer patient who is heterozygous for the UGT1A1 28 polymorphism (TA 6/7) as well as the UGT1A1 6 polymorphism (G/A). 23840132 2013
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 GeneticVariation disease BEFREE In this study, we determined the dose, efficacy, and tolerability of irinotecan according to UGT1A1 genotypes when combined with capecitabine in patients with metastatic colorectal cancer. 23595344 2013
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 GeneticVariation disease BEFREE UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. 24033692 2013
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 GeneticVariation disease BEFREE A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity. 22555197 2012
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 GeneticVariation disease BEFREE A distinct distribution pattern of UGT1A1 genotypes in Chinese patients might contribute to relatively low toxicity associated with irinotecan and 5-fluorouracil in mCRC patients. 23236239 2012
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 Biomarker disease BEFREE The purpose of this pharmacogenetic trial was to study the relevance of thymidylate synthase (TS) genotyping and of the isoform 1A1 of uridine diphosphate glucuronosyltransferase (UGT1A1) in order to tailor a combination chemotherapy regimen of 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in metastatic colorectal cancer. 21273624 2011
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.100 GeneticVariation disease BEFREE However, homozygosity for UGT1A1 28 or UGT1A1 6 and double heterozygosity for both UGT1A1 28 and UGT1A1 6 were significantly associated with severe neutropenia in metastatic colorectal cancer patients (P< 0.001). 21303789 2011